New gene-editing therapy shows early success in fighting advanced GI cancers

University of Minnesota researchers conducted a clinical trial using CRISPR gene-editing to enhance the immune system's fight against advanced gastrointestinal cancers. The study, published in Lancet Oncology, modified tumor-infiltrating lymphocytes by deactivating the CISH gene. Tested on 12 end-stage patients, the treatment showed promising safety results and potential effectiveness, with one patient experiencing a complete response lasting over two years. Efforts are ongoing to improve and streamline the approach for future trials.